AXL: Tyrosine-protein kinase receptor UFO
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding growth factor GAS6 and which is thus regulating many physiological processes including cell survival, cell proliferation, migration and differentiation.
- Drugs that act on it: 6
- Approved: 1
- In phases 1 to 3: 5
- Sponsors: 4
Who is on it, and how far along
Every drug ChEMBL records acting on AXL, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 3
- Antibody-drug conjugate 2
- Other 1
Approved1
Phase 30
Phase 24
Phase 11
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Astellas Pharma117%
- BerGenBio ASA117%
- Betta Pharmaceuticals Co., Ltd.117%
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd117%
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 6 act as: Tyrosine-protein kinase receptor UFO inhibitor; the rest name their own mechanism.| GilteritinibBoxed warning | Approved | Astellas Pharma | Small molecule | Inhibitor | 43 |
| Bemcentinib | Phase 2 | BerGenBio ASA | Small molecule | Inhibitor | 2 |
| Enapotamab vedotin | Phase 2 | — | Antibody-drug conjugate | Binding agentTyrosine-protein kinase receptor UFO binding agent | 0 |
| Mecbotamab vedotin | Phase 2 | — | Antibody-drug conjugate | Binding agentTyrosine-protein kinase receptor UFO binding agent | 0 |
| Ningetinib | Phase 2 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Small molecule | Inhibitor | 0 |
| BPI-9016 | Phase 1 | Betta Pharmaceuticals Co., Ltd. | Other | Inhibitor | 0 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 10 in all, from ClinicalTrials.gov.| Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia | Gilteritinib | Phase 2 | Not yet recruiting | Florian Kuchenbauer | Aug 10, 2026 |
| DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML | Gilteritinib | Phase 3 | Recruiting | The Second Affiliated Hospital of Kunming Medical University | Jul 20, 2026 |
| Study of SA+X in the Treatment of Newly Diagnosed AML | Gilteritinib | Phase 2 | Recruiting | Ruijin Hospital | Apr 23, 2026 |
| Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma | Bemcentinib | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Apr 17, 2026 |
| MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib | Gilteritinib | Phase 3 | Recruiting | The First Affiliated Hospital of Soochow University | Mar 11, 2026 |
| Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma | Bemcentinib | Phase 3 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Mar 3, 2026 |
| FLT3-ITD Targeted Therapy in Fit AML Patients | Gilteritinib | Phase 2 / Phase 3 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | Feb 23, 2026 |
| VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML | Gilteritinib | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | Feb 12, 2026 |
| Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML | Gilteritinib | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | Dec 2, 2025 |
| A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) | Gilteritinib | Phase 1 | Recruiting | Astellas Pharma Global Development, Inc. | Aug 24, 2025 |
Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Neurodegenerative disease
- 0.57
- Alzheimer disease
- 0.54
- Parkinson disease
- 0.53
- Lysosomal storage disease
- 0.53
- Dengue disease
- 0.51
- Neoplasm
- 0.41
- Myeloid leukemia
- 0.40
- Acute myeloid leukemia by FAB classification
- 0.38
- Head and neck squamous cell carcinoma
- 0.33
- NK-cell enteropathy
- 0.26
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4895, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P30530, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets